Retatrutide: Lilly plans FDA filing in 2027

Eli Lilly announced in July 2026 that it will file an application with the US Food and Drug Administration for retatrutide, its investigational triple receptor agonist, in the first quarter of 2027^[1]. The filing timeline rests on data from two newly completed Phase 3 trials in the TRIUMPH programme, TRIUMPH-2 (type-2 diabetes with obesity) and TRIUMPH-3 (obesity with established cardiovascular disease), which Lilly presented alongside a 104-week extension of TRIUMPH-1.

What the new TRIUMPH data shows

TRIUMPH-2 tested retatrutide in adults with type-2 diabetes and obesity or overweight. At the highest dose over 80 weeks, participants lost a mean 21% of body weight^[1]. TRIUMPH-3 enrolled adults with obesity and established cardiovascular disease; that group lost a mean 23% at 80 weeks on the top dose. Both results were in line with analyst expectations: patients with underlying conditions typically lose somewhat less weight on incretin-class drugs than the general obesity population, and both figures sit above the Phase 3 tirzepatide and semaglutide benchmarks in comparable populations.

The TRIUMPH-1 extension, which followed participants to 104 weeks rather than the original 80-week primary endpoint, reported 30% mean body-weight loss on 12 mg retatrutide^[1]. That figure comes from a subset with baseline BMI at or above 35. The 80-week headline from TRIUMPH-1 was 28.3% on 12 mg versus 2.2% on placebo, which the Phase 2 and Phase 3 literature for the triple agonist class^[2] had pointed toward.

The cardiovascular question the data raised

TRIUMPH-3 produced a finding that analysts flagged as worth watching. In the treatment arm, 27 participants experienced a MACE-3 event (cardiovascular death, heart attack, or stroke), compared with 23 in the placebo arm^[1]. A broader MACE-5 count, which includes all-cause death, did favour the treatment group. Analysts noting the imbalance were quick to say that the sample size and trial duration make it hard to draw firm conclusions: TRIUMPH-3 was not designed as a cardiovascular outcomes trial. The dedicated outcomes study, TRIUMPH-Outcomes, follows roughly 10,000 participants and has a primary completion date of February 2029^[3].

The cardiovascular signal is not unusual in itself. Short-duration trials in high-risk cardiovascular populations often show numerical imbalances that do not persist in longer, adequately powered outcomes studies. The same uncertainty surrounded earlier GLP-1 class programmes before the SELECT (semaglutide), SURMOUNT-MMO (tirzepatide) and LEADER (liraglutide) trials resolved the question. TRIUMPH-Outcomes is the trial that will resolve it for retatrutide, and it will not read out before the FDA reviews the initial application.

Why the filing is delayed to Q1 2027

Lilly cited manufacturing and quality-control data as the reason the submission will not happen sooner. The company needs to package the full TRIUMPH dataset with production-scale chemistry, manufacturing, and controls documentation before filing an NDA. A Q1 2027 submission, if on schedule, would place an FDA decision in late 2027 or early 2028 under a standard 12-month review clock, though the agency can grant priority review if it sees a sufficiently unmet need.

Retatrutide remains investigational. There is no FDA approval, no EMA marketing authorisation, no MHRA approval, and no marketing authorisation in any jurisdiction we cover. The regulatory position for each country is on the retatrutide regulation pages. Compounded and grey-market retatrutide has been available in some channels ahead of any approval; the FDA has treated these as unapproved products regardless of how vendors label them.

What is not settled by this data package

Three open questions matter for anyone following the approval path. First, the cardiovascular outcomes question: TRIUMPH-Outcomes is the only study that can settle whether retatrutide reduces or increases MACE in a longer, adequately powered trial. Second, the head-to-head question: TRIUMPH-5 compares retatrutide directly to tirzepatide, and that result has not yet been announced. Third, durability: the 104-week TRIUMPH-1 extension shows weight loss continuing to accumulate, but long-term maintenance after years of treatment, and after discontinuation, remains an open data gap.

The Phase 3 programme design is described in the published trial rationale by Giblin and colleagues (Diabetes, Obesity and Metabolism, 2026)^[4], which covers the basket-trial design that let TRIUMPH-1 and TRIUMPH-2 embed nested sleep-apnea and knee-osteoarthritis protocols alongside the primary weight-management endpoint. That design is the reason the TRIUMPH programme generated broader secondary data than a conventional obesity trial.

Where retatrutide sits right now

Investigational. The TRIUMPH data package is the largest body of evidence on retatrutide to date, and it positions Lilly to file. Approval is a separate step and on a timeline that runs past 2027. For context on the Phase 2 evidence that preceded this Phase 3 programme, the Jastreboff and colleagues obesity trial published in the New England Journal of Medicine (2023)^[2] remains the foundational peer-reviewed readout. The full TRIUMPH-1 dataset has not yet appeared in a peer-reviewed journal; the TRIUMPH-2 and TRIUMPH-3 data are currently topline only.

The retatrutide peptide page tracks regulatory status, the TRIUMPH programme timeline, and the grey-market context. This article will update when the FDA submission is confirmed and when any priority-review designation is announced.